According to the report “Uterine Cancer Therapeutics Market“, published by Market Data Forecast, the global market is projected to reach USD 22,686.3 million by 2021, at a CAGR of 5.45% from 2016 to 2021.
Uterine cancer is one of most commonly prevailing malignant tumours that starts in the cells of the uterus and spreads to other parts of the body. Uterine cancer is mainly of two types such as uterine sarcoma and endometrial carcinoma. Till now more numbers of therapies have been evolved to manage uterine cancer types include surgery, chemotherapy, radiation therapy, immunotherapy, and hormone therapy. Global market for Uterine Cancer Therapeutics is driven by the increasing advancements in molecular diagnostics industry to support target specific therapies and rising number of newly diagnosed uterine cancer cases.
Increasing healthcare expenditure, rising focus of government to provide effective healthcare solutions, and growing advancements in the cancer screening & treatment methods are also driving the growth of global Uterine Cancer Therapeutics market. In addition, increasing advancements in molecular diagnostics industry to support target specific therapies and rising awareness among patients is further stimulating the global Uterine Cancer Therapeutics market. However, dearth of superior healthcare infrastructure in certain developing countries, lack of efficient communication between women & health care providers, high cost of the uterine cancer treatment solutions, improper reimbursement policies, and stringent regulatory framework are restraining the growth of global Uterine Cancer Therapeutics market.
Global Market for Uterine Cancer Therapeutics is segmented by type, therapy and region.
- By Type
- Endometrial Carcinoma
- Squamous cell carcinoma
- Uterine Sarcoma
- By Therapy
- Radiation Therapy
- Hormone Therapy
- By Geography
- North America
- Latin America
- Middle-East & Africa
Abbott Laboratories (U.S.), Ariad Pharmaceuticals, Inc. (U.S.), Becton, Dickinson and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline Plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Siemens Healthcare GmbH (Germany), and Takeda Pharmaceutical Company Ltd. (Japan).
About Market Data Forecast:
Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organisation that’s trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.
Market Data Forecast, Inc.
+1-888-702-9626 (U.S. TOLL-FREE)